In 2-4 % of patients with histologically proven cancer, the primary tumor cannot be localized, even by use of modern diagnostic methods. This situation is clinically described as cancer of unknown primary (CUP) [ 1 , 2 ] and has a frequency similar to pancreatic cancer, renal cell carcinoma, or leukemia [ 3 ]. Even after extensive diagnostic workup using state-of-the-art methods, less than 20 % of primary tumors are localized antemortem, compared to almost 80 % of primary tumors identifi ed in postmortem autopsy series [ 4 ].CUP tumors are adenocarcinomas in 40-60 %, undifferentiated carcinomas in 15-20 %, squamous cell carcinomas in 5-8 %, and neuroendocrine tumors in 3-5 %; 1-3 % of all CUP belong to other entities [ 5 ]. Most frequently, primary tumors are localized in the lung (20-35 %) and the pancreas (15-20 %), followed by other gastrointestinal and gynecological malignancies. Median survival in this heterogenic group of cancer patients is only 3-11 months [ 6 ]. Imaging is essential in all four steps of the diagnostic and therapeutic management of CUP patients [ 7 ]: localization of the primary tumor, identifi cation of all manifestations, identifi cation of potentially treatable tumors (i.e., breast cancer, prostate carcinoma, lymphoma, etc.), and characterization of the clinicopathological entity and stratifi cation into subsets with favorable prognosis (approximately 20 %) with differentiated and/or chemosensitive tumors for which specifi c treatment options are available and, on